Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort

S.M. Laville, M. Metzger, B. Stengel, C. Jacquelinet, C. Combe, D. Fouque, M. Laville, L. Frimat, C. Ayav, E. Speyer, B.M. Robinson, Z.A. Massy, S. Liabeuf

British Journal of Clinical Pharmacology

Corresponding author:

Bénédicte Stengel
Director, Inserm U1018, Team 5
UPS-UVSQ, CESP, Centre for Epidemiology and Population Health
EpReC Team, Renal and Cardiovascular Epidemiology
16, avenue P. Vaillant Couturier
94 807 Villejuif cedex
France
Phone: + 33 1 4559 5039
E-mail: benedicte.stengel@inserm.fr

Supplementary Table 4: Agreement between the CKD-EPI or de-indexed CKD-EPI equations and Cockcroft-Gault equation

A. Agreement in evaluating contraindications (CIs) B. Agreement in evaluating inappropriately high doses (IHDs)

A. Agreement in evaluating contraindications (CIs)

		CKD-EPI		De-indexed CKD-EPI	
		No CI	CI	No CI	CI
Cockcroft-Gault	No CI	22396 (94.3%)	557 (2.3%)	22646 (95.4%)	307 (1.3%)
	CI	61 (0.3%)	728 (3.1%)	33 (0.1%)	756 (3.2%)
Kappa coefficient		κ CG vs. CKD-EPI= **0.69**		κ CG vs. De-indexed CKD-EPI= **0.81**	

B. Agreement in evaluating inappropriately high doses (IHDs)

		CKD-EPI		De-indexed CKD-EPI	
		No IHD	IHD	No IHD	IHD
Cockcroft-Gault	No IHD	21785 (94.3%)	337 (1.5%)	21507 (94.9%)	178 (0.8%)
	IHD	47 (0.2%)	938 (4.0%)	31 (0.1%)	952 (4.2%)
Kappa coefficient		κ CG vs. CKD-EPI= **0.82**		κ CG vs. De-indexed CKD-EPI= **0.90**	